by GlyTherix | Jan 13, 2025
On 13 January 2025, GlyTherix Ltd and Eckert & Ziegler announced the expansion of their existing Lutetium-177-based collaboration with a global supply agreement for Actinium-225. Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical...
by GlyTherix | Jan 10, 2025
Exciting News from GlyTherix at JPM Healthcare Week 2025!We’re thrilled to announce that GlyTherix, a leader in targeted radiotherapy, will be showcasing its cutting-edge technology at two major events during JPM Healthcare Week in San Francisco. Wuxi Apptec Global...
by GlyTherix | Dec 10, 2024
GlyTherix and Nusano, a physics company transforming the production of radioisotopes, today announced a supply agreement for non-carrier-added lutetium-177 (Lu-177). The agreement also provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production,...
by GlyTherix | Oct 18, 2024
We are pleased to announce GlyTherix is presenting an e-poster titled “Determination of Optimal Imaging Dose of [89Zr]Zr-DFO-Miltuximab and Maximum Tolerated Therapeutic Dose of [177Lu]Lu-DOTA-Miltuximab.” This will showcase our groundbreaking research in...
by GlyTherix | Oct 8, 2024
Exciting News in Targeted Radiotherapy! GlyTherix Ltd has signed a global clinical supply agreement with Eckert & Ziegler, a leader in isotopes for nuclear medicine. This collaboration will provide GMP-grade Lutetium-177 chloride for GlyTherix’s clinical...
by GlyTherix | Sep 18, 2024
GlyTherix is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE Technologies, a pioneer in next-generation fusion-based technology and North America’s largest producer of non-carrier added lutetium-177 (n.c.a. Lu-177) chloride....
